Lp(a): The Hidden Heart Risk Your Doctor Probably Never Tested
Lipoprotein(a) is an independent, largely genetic risk factor for cardiovascular disease that affects 1 in 5 people. Standard lipid panels don't include it. Here's why it matters and what you can do.
What Is Lp(a)?
Lipoprotein(a) — abbreviated Lp(a) and pronounced "L-P-little-a" — is a type of LDL particle with an extra protein called apolipoprotein(a) attached. This structural difference makes it significantly more atherogenic (plaque-forming) than regular LDL.
Lp(a) levels are 80–90% genetically determined and remain largely stable throughout adult life. Unlike LDL, they are not meaningfully affected by diet or most lifestyle interventions.
Why It Matters
Elevated Lp(a) is an independent risk factor for:
- Coronary artery disease — 2–3x increased risk at high levels
- Stroke — particularly ischemic stroke
- Aortic stenosis — Lp(a) deposits in heart valves
- Peripheral artery disease
A 2022 meta-analysis of 43 studies (n > 200,000) found that Lp(a) above 50 mg/dL was associated with a 2.4x increased risk of major cardiovascular events, independent of LDL, HDL, and other traditional risk factors.
What's the Optimal Level?
| Level | Risk Category |
| < 30 mg/dL | Low risk |
| 30–50 mg/dL | Borderline |
| 50–100 mg/dL | High risk |
| > 100 mg/dL | Very high risk |
Approximately 20% of the population has Lp(a) above 50 mg/dL. Most of them have never been tested.
Why Isn't It Tested Routinely?
Until recently, there were no approved treatments specifically targeting Lp(a), so many guidelines didn't recommend routine testing. That's changing rapidly:
- Pelacarsen (Novartis) — an antisense oligonucleotide that reduces Lp(a) by 80–90%, currently in Phase 3 trials
- Muvalaplin (Eli Lilly) — a small molecule inhibitor, Phase 2 results showed 65% reduction
- Olpasiran (Amgen) — siRNA therapy, Phase 3 ongoing
The ESC/EAS 2019 guidelines now recommend testing Lp(a) at least once in every adult's lifetime.
What Can You Do Now?
While waiting for approved treatments, people with high Lp(a) should:
- Aggressively control other risk factors — get LDL below 70 mg/dL, manage blood pressure, don't smoke
- Consider aspirin — low-dose aspirin may partially offset Lp(a)'s prothrombotic effects (discuss with your doctor)
- Niacin — reduces Lp(a) by 20–30% but has cardiovascular outcome data that is mixed
- PCSK9 inhibitors — reduce Lp(a) by 20–30% as a secondary effect
Body150 flags elevated Lp(a) in your risk map and includes it in your cardiovascular risk assessment alongside LDL, ApoB, and CRP.
Check your biomarkers in Body150
Upload your blood tests and get personalized insights based on your genetics and health profile.
Open App